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SECTION I: USE OF THE CLINICAL PRACTICE GUIDELINE
This Clinical Practice Guideline document is based upon systematic literature searches last
conducted in January 2011, supplemented with additional evidence through November 2011.
It is designed to provide information and assist decision-making. It is not intended to define a
standard of care, and should not be construed as one, nor should it be interpreted as prescribing
an exclusive course of management. Variations in practice will inevitably and appropriately occur
when clinicians take into account the needs of individual patients, available resources, and
limitations unique to an institution or type of practice. Every health-care professional making
use of these recommendations is responsible for evaluating the appropriateness of applying them
in the setting of any particular clinical situation. The recommendations for research contained
within this document are general and do not imply a specific protocol.
SECTION II: DISCLOSURE
Kidney Disease: Improving Global Outcomes (KDIGO) makes every effort to avoid any actual or
reasonably perceived conflicts of interest that may arise as a result of an outside relationship or a
personal, professional, or business interest of a member of the Work Group. All members of the
Work Group are required to complete, sign, and submit a disclosure and attestation form
showing all such relationships that might be perceived or actual conflicts of interest. This
document is updated annually and information is adjusted accordingly. All reported information
will be printed in the final publication and are on file at the National Kidney Foundation (NKF),
Managing Agent for KDIGO.
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